Cargando…

Comprehensive Evaluation of the NeoBase 2 Non-derivatized MSMS Assay and Exploration of Analytes With Significantly Different Concentrations Between Term and Preterm Neonates

BACKGROUND: Despite the popularity of the NeoBase 2 Non-derivatized MSMS assay (PerkinElmer, Turku, Finland), there are no reports of its comprehensive evaluation, including the ability to distinguish transient tyrosinemia of the newborn (TTN) from tyrosinemia type 1 (TYR 1) using succinylacetone (S...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Beomki, Heo, Won Young, Kim, Jee Ah, Lee, Hyun-Seung, Hwang, Narae, Park, Hyung-Doo, Sung, Se In, Chang, Yun Sil, Park, Won Soon, Lee, Soo-Youn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society for Laboratory Medicine 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9618896/
https://www.ncbi.nlm.nih.gov/pubmed/36281509
http://dx.doi.org/10.3343/alm.2023.43.2.153
_version_ 1784821155294609408
author Lee, Beomki
Heo, Won Young
Kim, Jee Ah
Lee, Hyun-Seung
Hwang, Narae
Park, Hyung-Doo
Sung, Se In
Chang, Yun Sil
Park, Won Soon
Lee, Soo-Youn
author_facet Lee, Beomki
Heo, Won Young
Kim, Jee Ah
Lee, Hyun-Seung
Hwang, Narae
Park, Hyung-Doo
Sung, Se In
Chang, Yun Sil
Park, Won Soon
Lee, Soo-Youn
author_sort Lee, Beomki
collection PubMed
description BACKGROUND: Despite the popularity of the NeoBase 2 Non-derivatized MSMS assay (PerkinElmer, Turku, Finland), there are no reports of its comprehensive evaluation, including the ability to distinguish transient tyrosinemia of the newborn (TTN) from tyrosinemia type 1 (TYR 1) using succinylacetone (SUAC). No newborn screening (NBS) cutoffs for preterm neonates in the Korean population have been suggested. We evaluated the NeoBase 2 assay and identified analytes requiring different cutoffs in preterm neonates. METHODS: Residual NBS dried blood spot samples and proficiency testing (PT) materials of the Newborn Screening Quality Assurance Program and the Korean Association of External Quality Assessment Service were used. Precision, accuracy, limit of detection (LOD), lower limit of quantification (LLOQ), linearity, recovery, carryover, and performance of SUAC were evaluated. Cutoffs were determined, and analytes requiring different cutoffs in preterm neonates were investigated. RESULTS: Mean CVs for within-run and between-day precision were within 15%. Accuracy analysis indicated high agreement with in-house derivatized assay results and results of other PT participants. All analytes demonstrated acceptable LOD, LLOQ, and linearity. Recoveries were acceptable, except for SUAC. Carryover was negligible. Cutoffs were established for all analytes; Tyr, adenosine, and C200-lysophosphatidylcholine required different cutoffs in preterm neonates. Differential diagnosis of TYR 1 and TTN was successful with simultaneous Tyr and SUAC measurement. CONCLUSIONS: The NeoBase 2 assay demonstrated satisfactory performance. The additional analytes provide a wider diagnostic coverage, and the simultaneous measurement of Tyr and SUAC is efficient in excluding TYR 1. The new cutoffs for preterm neonates may decrease false-positive rates, without compromising diagnostic sensitivity.
format Online
Article
Text
id pubmed-9618896
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Korean Society for Laboratory Medicine
record_format MEDLINE/PubMed
spelling pubmed-96188962022-12-26 Comprehensive Evaluation of the NeoBase 2 Non-derivatized MSMS Assay and Exploration of Analytes With Significantly Different Concentrations Between Term and Preterm Neonates Lee, Beomki Heo, Won Young Kim, Jee Ah Lee, Hyun-Seung Hwang, Narae Park, Hyung-Doo Sung, Se In Chang, Yun Sil Park, Won Soon Lee, Soo-Youn Ann Lab Med Original Article BACKGROUND: Despite the popularity of the NeoBase 2 Non-derivatized MSMS assay (PerkinElmer, Turku, Finland), there are no reports of its comprehensive evaluation, including the ability to distinguish transient tyrosinemia of the newborn (TTN) from tyrosinemia type 1 (TYR 1) using succinylacetone (SUAC). No newborn screening (NBS) cutoffs for preterm neonates in the Korean population have been suggested. We evaluated the NeoBase 2 assay and identified analytes requiring different cutoffs in preterm neonates. METHODS: Residual NBS dried blood spot samples and proficiency testing (PT) materials of the Newborn Screening Quality Assurance Program and the Korean Association of External Quality Assessment Service were used. Precision, accuracy, limit of detection (LOD), lower limit of quantification (LLOQ), linearity, recovery, carryover, and performance of SUAC were evaluated. Cutoffs were determined, and analytes requiring different cutoffs in preterm neonates were investigated. RESULTS: Mean CVs for within-run and between-day precision were within 15%. Accuracy analysis indicated high agreement with in-house derivatized assay results and results of other PT participants. All analytes demonstrated acceptable LOD, LLOQ, and linearity. Recoveries were acceptable, except for SUAC. Carryover was negligible. Cutoffs were established for all analytes; Tyr, adenosine, and C200-lysophosphatidylcholine required different cutoffs in preterm neonates. Differential diagnosis of TYR 1 and TTN was successful with simultaneous Tyr and SUAC measurement. CONCLUSIONS: The NeoBase 2 assay demonstrated satisfactory performance. The additional analytes provide a wider diagnostic coverage, and the simultaneous measurement of Tyr and SUAC is efficient in excluding TYR 1. The new cutoffs for preterm neonates may decrease false-positive rates, without compromising diagnostic sensitivity. Korean Society for Laboratory Medicine 2023-03-01 2022-10-25 /pmc/articles/PMC9618896/ /pubmed/36281509 http://dx.doi.org/10.3343/alm.2023.43.2.153 Text en © Korean Society for Laboratory Medicine https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0 (https://creativecommons.org/licenses/by-nc/4.0/) ) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Lee, Beomki
Heo, Won Young
Kim, Jee Ah
Lee, Hyun-Seung
Hwang, Narae
Park, Hyung-Doo
Sung, Se In
Chang, Yun Sil
Park, Won Soon
Lee, Soo-Youn
Comprehensive Evaluation of the NeoBase 2 Non-derivatized MSMS Assay and Exploration of Analytes With Significantly Different Concentrations Between Term and Preterm Neonates
title Comprehensive Evaluation of the NeoBase 2 Non-derivatized MSMS Assay and Exploration of Analytes With Significantly Different Concentrations Between Term and Preterm Neonates
title_full Comprehensive Evaluation of the NeoBase 2 Non-derivatized MSMS Assay and Exploration of Analytes With Significantly Different Concentrations Between Term and Preterm Neonates
title_fullStr Comprehensive Evaluation of the NeoBase 2 Non-derivatized MSMS Assay and Exploration of Analytes With Significantly Different Concentrations Between Term and Preterm Neonates
title_full_unstemmed Comprehensive Evaluation of the NeoBase 2 Non-derivatized MSMS Assay and Exploration of Analytes With Significantly Different Concentrations Between Term and Preterm Neonates
title_short Comprehensive Evaluation of the NeoBase 2 Non-derivatized MSMS Assay and Exploration of Analytes With Significantly Different Concentrations Between Term and Preterm Neonates
title_sort comprehensive evaluation of the neobase 2 non-derivatized msms assay and exploration of analytes with significantly different concentrations between term and preterm neonates
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9618896/
https://www.ncbi.nlm.nih.gov/pubmed/36281509
http://dx.doi.org/10.3343/alm.2023.43.2.153
work_keys_str_mv AT leebeomki comprehensiveevaluationoftheneobase2nonderivatizedmsmsassayandexplorationofanalyteswithsignificantlydifferentconcentrationsbetweentermandpretermneonates
AT heowonyoung comprehensiveevaluationoftheneobase2nonderivatizedmsmsassayandexplorationofanalyteswithsignificantlydifferentconcentrationsbetweentermandpretermneonates
AT kimjeeah comprehensiveevaluationoftheneobase2nonderivatizedmsmsassayandexplorationofanalyteswithsignificantlydifferentconcentrationsbetweentermandpretermneonates
AT leehyunseung comprehensiveevaluationoftheneobase2nonderivatizedmsmsassayandexplorationofanalyteswithsignificantlydifferentconcentrationsbetweentermandpretermneonates
AT hwangnarae comprehensiveevaluationoftheneobase2nonderivatizedmsmsassayandexplorationofanalyteswithsignificantlydifferentconcentrationsbetweentermandpretermneonates
AT parkhyungdoo comprehensiveevaluationoftheneobase2nonderivatizedmsmsassayandexplorationofanalyteswithsignificantlydifferentconcentrationsbetweentermandpretermneonates
AT sungsein comprehensiveevaluationoftheneobase2nonderivatizedmsmsassayandexplorationofanalyteswithsignificantlydifferentconcentrationsbetweentermandpretermneonates
AT changyunsil comprehensiveevaluationoftheneobase2nonderivatizedmsmsassayandexplorationofanalyteswithsignificantlydifferentconcentrationsbetweentermandpretermneonates
AT parkwonsoon comprehensiveevaluationoftheneobase2nonderivatizedmsmsassayandexplorationofanalyteswithsignificantlydifferentconcentrationsbetweentermandpretermneonates
AT leesooyoun comprehensiveevaluationoftheneobase2nonderivatizedmsmsassayandexplorationofanalyteswithsignificantlydifferentconcentrationsbetweentermandpretermneonates